tirzepatide and fatty liver disease for & NASH Tirzepatide for MASH with Liver

As previously reported, the reduction of inflammation may be related to weight loss, that was significant in the different outcome trials, going from a 0.6-kg reduction at 12 weeks with Lixisenatide in ELIXA trial to 4.3 kg at 2 years with injectable semaglutide in SUSTAIN-6 trial [25, 26]

This occurs due to metabolic adaptations including increased hunger hormones and decreased energy expenditure that persist after weight loss

The agitation introduces air bubbles that create foam, and the foam-liquid interfaces generate shear stress that denatures the protein

FIGURE 4 Flow cytometry analysis provided additional insights into the immune-modulatory effects of CTS